Guangdong True Health completes preclinical xenogeneic liver perfusion study with 144-hour support record

• Guangdong True Health Medical Technology Development reported preclinical progress in extracorporeal liver perfusion support using its in-house organ perfusion system.
• Results have already been generated in six animal-model studies; no future presentation date was disclosed.
• Work showed sustained liver-support activity with stable function over an extended period, supporting feasibility for longer-duration perfusion support.
• Management flagged potential path toward clinical trials, while stressing the program remains exploratory with no human safety or efficacy established.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong True Health Medical Technology Development Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261012-12369786), on October 12, 2026, and is solely responsible for the information contained therein.